drugset / Trial / NCT01717157

A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers

NCT01717157

Phase 1 Completed 32 enrolled Janssen Research & Development, LLC
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics and relative bioavailability of 4 new formulations of fentanyl transdermal patch in healthy participants after a single application for 72 hours.

Timeline

Start
2012-08
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified 6.2 mg Topical
Subject Fentanyl Other / unclassified 7.1 mg Topical
Subject Fentanyl Other / unclassified 8.4 mg Topical
Subject Fentanyl Other / unclassified 11 mg Topical

Indications

No indication recorded.